CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.

  • Year: 2011
  • Date: 2011
  • Author: Lenney W
Source

J Cyst Fibros. 2011 Jan;10(1):9-14.

Study design (if review, criteria of inclusion for studies)

single-dose, open-label, two-way crossover study

Participants

13 participants aged 18 - 65 years. 7 with CF with chronic PsA infection and FEV1 equal to or above 25% predicted. 6 healthy volunteers with FEV1 equal to or over 80% predicted and BMI within ± 25% of ideal.

Interventions

subjects were randomised to receive tobramycin via eFlow rapid or LC Plus jet nebuliser.

Outcome measures

Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacokinetics, and safety were evaluated.

Main results

In CF patients, whole-lung deposition was 40% less with the eFlow rapid compared with LC Plus nebulisers (8.9 +/- 0.8%, and 15.1 +/- 6.0%, p>0.05). Nebulisation time was shorter with eFlow rapid compared to LC Plus (7.0min versus 20.0min, p<0.05). Lung deposition in healthy subjects was comparable between both devices.

Authors' conclusions

eFlow rapid reduces the nebulisation time of tobramycin and can potentially improve compliance in patients with CF.

Related topics

Antibiotic treatment of early pseudomonas aeruginosa

Antibiotics for pulmonary exacerbations

Inhaled antibiotics in cystic fibrosis

MRSA eradication in CF

Prophylactic use of oral antistaphylococcal antibiotic

Scheduled antibiotics every 3-4 months / symptom-based treatment

Keywords: Adolescent; Adult; Aged; Anti-Bacterial Agents; Inhalation OR nebulised; nebuliser; non pharmacological intervention - devices OR physiotherapy; pharmacological_intervention; Tobramycin; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Aminoglycosides;